Colorectal Cancer Stage III Clinical Trial
Official title:
Epidemiological Study to Determine the Prevalence of ctDNA Positivity in Participants With Stage II (High Risk) or Stage III CRC After Surgery With Curative (R0) Intent and Subsequent Adjuvant Chemotherapy With Monitoring of ctDNA During Clinical Follow-up
NCT number | NCT04813627 |
Other study ID # | BNT000-001 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | July 2, 2021 |
Est. completion date | July 2024 |
This is a multi-site epidemiological study designed to monitor circulating tumor DNA (ctDNA) status in participants with Stage II (high risk)/III colorectal cancer (CRC) following resection/prior to adjuvant chemotherapy (AdCTx), during the course of AdCTx and for a period of 630 days thereafter, according to CRC stages and disease characteristics. Participants receive no therapeutic intervention as part of this study. This study will identify participants who might be potential candidates for the clinical trial BNT122-01 (NCT04486378), a study of RO7198457 after completion of standard AdCTx in this patient population. Based on the eligibility criteria for that trial, this study will identify participants with confirmed Stage II (high risk)/III CRC that are positive for ctDNA after resection and are therefore at high risk of disease recurrence to enrich the BNT122-01 study cohort. These participants will have the option to enter screening for BNT122-01 at Screening Visit 2 of that trial if they meet the eligibility criteria of BNT000-001 during screening. Data from the assessments from BNT000-001 will be carried across to the BNT122-01 trial where feasible.
Status | Recruiting |
Enrollment | 1500 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Must have given informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. - Age = 18 years old at time of signing the informed consent form. - Ability to comply with the study protocol, in the investigator's judgment. - Must have Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer per AJCC 2017 that has been surgically totally resected (R0 confirmed by pathology report). Stage II (high risk) colon cancer is defined as (any of): - T4 - Grade = 3 - Clinical presentation with bowel obstruction or perforation - Histological signs of vascular, lymphatic or perineural invasion - < 12 nodes examined - Adequate tumor material in formalin-fixed paraffin embedded (FFPE) blocks or as sectioned tissue (only upon approval by sponsor) must be available, preferably from resection. The specimen should be submitted along with an associated pathology report. Multiple samples may be provided as available, but priority should be given to tissue with the highest tumor content and lowest necrotic area. - Intention to receive a standard of care adjuvant chemotherapy (AdCTx) within 8 weeks post-surgery, and be scheduled for at least 3 months of treatment (including rest days) according to the treating physician or investigator. - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. - Adequate end-organ function. Exclusion Criteria: - Induction of neoadjuvant systemic therapy prior to resection of CRC. - Prior systemic investigational therapy. - Positive serology for hepatitis B (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy): - Positive test for antibodies to hepatitis B core antigens (anti HBc) and - Negative test for antibodies to hepatitis B surface antigens (anti HBs). - Active hepatitis C virus (HCV) infection; participants who have completed curative antiviral treatment with HCV viral load below the limit of quantification by polymerase chain reaction (PCR) are allowed. - Participant has a history of human immunodeficiency virus (HIV) antibody positivity, or tests positive for HIV at screening. - Residual tumor classification following surgery other than R0 (microscopic margin-negative resection). - Participants with known past or current malignancy other than inclusion diagnosis, except for: - Cervical carcinoma of Stage 1B or less. - Non-invasive basal cell or squamous cell skin carcinoma. - Non-invasive, superficial bladder cancer. - Prostate cancer with a current PSA level < 0.1 ng/mL. - Any curable cancer with a complete response (CR) of > 2 years duration. - Participant has not started standard of care AdCTx within 8 weeks post-surgery. - Participant has received less than 3 months (including rest days) of AdCTx treatment. - Inadequate tumor material (either quality or quantity) to support circulating tumor DNA (ctDNA) analysis. - Participants who have had prior splenectomy. |
Country | Name | City | State |
---|---|---|---|
Belgium | ZNA Campus Middelheim | Antwerpen | |
Belgium | Imelda Ziekenhuis | Bonheiden | |
Belgium | VZW Algemeen Ziekenhuis KLINA | Brasschaat | |
Belgium | Algemeen Ziekenhuis Sint-Lucas | Brugge | |
Belgium | Universitair Ziekenhuis Brussel (UZ-VUB - Academisch Ziekenhuis) | Jette | |
Belgium | AZ Groeninge | Kortrijk | |
Belgium | Centres Hospitaliers Jolimont | La Louvière | |
Belgium | Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg | Leuven | |
Belgium | Clinique et Maternite Sainte-Elisabeth (CMSE) | Namur | |
Belgium | Clinique Saint-Pierre d'ottignies (CSPO) | Ottignies | |
Belgium | Algemeen Ziekenhuis (AZ) Glorieux | Ronse | |
Belgium | Centre Hospitalier Regional, CHR | Verviers | |
Germany | Gemeinschaftspraxis Dr. med. B. Heinrich, Prof. M. Bangerter MD | Augsburg | |
Germany | Charité Campus Mitte (CCM) - Universitätsmedizin Berlin | Berlin | |
Germany | Universitaetsklinikum St. Josef-Hospital Bochum | Bochum | |
Germany | Medizinische Klinik III, Universitätsklinikum Bonn | Bonn | |
Germany | Cancer Center Donauwoerth and Dachau | Donauwoerth | |
Germany | St. Johannes Hospital | Dortmund | |
Germany | Asklepios MVZ Elmshorn | Elmshorn | |
Germany | Agaplesion Markus Krankenhaus | Frankfurt am Main | |
Germany | Centrum fuer Haematologie und Onkologie Bethanien | Frankfurt am Main | |
Germany | Klinikum der Johann Wolfgang Goethe-Universitaet Frankfurt | Frankfurt am Main | |
Germany | Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung | Frankfurt am Main | |
Germany | Studiengesellschaft BSF | Halle | |
Germany | Asklepios Klinik Altona | Hamburg | |
Germany | Asklepios Klinik St. Georg | Hamburg | |
Germany | Asklepios Kliniken Nord | Hamburg | |
Germany | Haematologisch-Onkologische Praxis Eppendorf HOPE | Hamburg | |
Germany | Medizinische Hochschule Hannover | Hannover | |
Germany | SLK-Kliniken Heilbronn GmbH | Heilbronn | |
Germany | Internistische Schwerpunktpraxis Hamatologie und Onkologie | Mainz | |
Germany | Ze:ro Arztpraxen | Mannheim | |
Germany | Klinikum der Universität München, Medizinische Klinik und Poliklinik III | München | |
Germany | Staedtisches Klinikum Muenchen GmbH, Klinikum Neuperlach | München | |
Germany | Prosper Hospital | Recklinghausen | |
Germany | Universitaetsmedizin Rostock | Rostock | |
Germany | Universitaetsklinikum Ulm | Ulm | |
Germany | Asklepios Klinik Weissenfels | Weißenfels | |
Germany | Helios Dr. Horst Schmidt Kliniken (HSK) | Wiesbaden | |
Germany | Forschungszentrum Ruhr | Witten | |
Spain | Centro Oncologico Galicia | A Coruña | |
Spain | Complejo Hospitalario Universitario A Coruna | A Coruña | |
Spain | Hospital Universitari Germans Trias - ICO Badalona | Badalona | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona | |
Spain | Hospital De Sant Joan Despi Moises Broggi | Barcelona | |
Spain | Hospital Universitari Vall d'Hebron | Barcelona | |
Spain | IOR- Instituto Quiron Dexeus | Barcelona | |
Spain | Hospital General De Granollers | Granollers | |
Spain | Hospital Sant Joan de Deu-Fundacio Althaia | Manresa | |
Spain | Complejo Hospitalario de Orense | Orense | |
Spain | Complejo Hospitalario de Navarra | Pamplona | |
Spain | Hospital Universitari Sant Joan de Reus | Reus | |
Spain | Corporacio Sanitaria Universitaria Parc Tauli | Sabadell | |
Spain | Complejo Hospitalario Universitario De Santiago De Compostela | Santiago De Compostela | |
Spain | Hospital Universitario Mutua de Terrassa | Terrassa | |
Spain | Hospital Universitario Miguel Servet | Zaragoza | |
United States | USOR - New York Oncology Hematology, P.C. | Albany | New York |
United States | Texas Oncology - Austin | Austin | Texas |
United States | Ridley-Tree Cancer Center | California City | California |
United States | Oncology Hematology Care Clinical Trials, LLC | Cincinnati | Ohio |
United States | John Muir Clinical Research Center | Concord | California |
United States | Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas |
United States | Cancer Care Specialists Of Central Illinois Sc (Ccsci) - Cancer Care Center Of Decatur | Decatur | Illinois |
United States | Rocky Mountain Cancer Centers - Denver Midtown | Denver | Colorado |
United States | USOR - Willamette Valley Cancer Institute and Research Center | Eugene | Oregon |
United States | Virginia Cancer Specialists, PC | Fairfax | Virginia |
United States | Marin Cancer Care | Greenbrae | California |
United States | The Oncology Institute of Hope | Los Angeles | California |
United States | Texas Oncology - San Antonio Medical Center | San Antonio | Texas |
United States | Orchard Healthcare Research Inc. | Skokie | Illinois |
United States | Rockwood Cancer Treatment Center | Spokane | Washington |
United States | Texas Oncology - Northeast Texas | Tyler | Texas |
United States | Northwest Cancer Specialists | Vancouver | Washington |
Lead Sponsor | Collaborator |
---|---|
BioNTech SE |
United States, Belgium, Germany, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence of ctDNA positivity in the post-surgery/pre-AdCTx blood sample | Blood sample taken post-surgery and pre-adjuvant chemotherapy. | 4 to 8 weeks after surgery and within 7 days prior up to the day of start of AdCTx | |
Primary | Occurrence of ctDNA positivity in the first post-AdCTx blood sample | Blood sample taken post-adjuvant chemotherapy. | 14 to 21 days after last AdCTx treatment | |
Secondary | Transfer of participants from the BNT000-001 study to the BNT122-01 clinical trial | The absolute and relative frequency of participants that will transfer to the BNT122-01 clinical trial from this epidemiological study will be reported. | 4 weeks following Visit 1 (upon availability of ctDNA positivity status) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01570452 -
Matrilysin Expression in Different Stages of Colorectal Tumors
|
N/A | |
Active, not recruiting |
NCT04304209 -
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04398446 -
Effect of Hemp-CBD on Patients With CIPN
|
Phase 2 | |
Recruiting |
NCT04486378 -
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT04264676 -
Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06314958 -
Stage II/III Colorectal Cancer Recurrence
|
||
Recruiting |
NCT06342440 -
Early Detection of Advanced Adenomas and Colorectal Cancer
|
||
Recruiting |
NCT04714814 -
Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
|
||
Recruiting |
NCT05898789 -
Virtual Rehabilitation for Cancer Survivors
|
N/A | |
Completed |
NCT01356264 -
Multimodal Prehabilitation for Colorectal Surgery
|
Phase 2 | |
Recruiting |
NCT03448549 -
SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients
|
Phase 3 | |
Recruiting |
NCT03904537 -
A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05131243 -
the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer
|
N/A | |
Recruiting |
NCT06076811 -
DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies
|
||
Recruiting |
NCT06111105 -
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
|
||
Recruiting |
NCT06342401 -
Early Onset Colorectal Cancer Detection
|
||
Completed |
NCT06271980 -
Early-Onset Colorectal Cancer Recurrence
|